Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-injectable formulation of Benlysta for patients with systemic lupus erythematosus, ...

GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have started clinical trials on a different version of lupus drug Benlysta that would be easier to administer to ...

The European Commission has approved a new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus ...

The European Medicines Agency (EMA) has recommended approval of a self-injectable form of belimumab (Benlysta, GlaxoSmithKline) as an add-on therapy for adults with the most common form of lupus, ...

WASHINGTON - The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development of other drugs ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a 200 mg Benlysta autoinjector for children aged 5 years and ...

WASHINGTON (CBSNewYork.com/AP) The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical ...

GlaxoSmithKline PLC (GSK.LN) Friday said it received U.S. Food and Drug Administration approval for a new self-injectable form of Benlysta, a treatment for the immune system disease systemic lupus ...

In adults and children five years and up Benlysta can be administered by a medical professional through an IV (intravenous) infusion directly into the vein; adults can self-administer an injection ...

GlaxoSmithKline PLC (GSK.LN) reported on Monday that it had received European marketing authorization for the self-injectable formulation of Benlysta--a drug for the treatment of systemic lupus ...

Years before Benlysta’s approval as the first new lupus treatment in more than 50 years, GlaxoSmithKline (NYSE:GSK) signed a development and commercialization agreement with Human Genome Sciences ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.